Innovent Biologics
Suzhou-based innovator of domestic PD-1 inhibitors and biosimilars, exporting oncology biologics under accelerated NMPA pathways.
- Country
- China
mAbs
cn
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.